Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vor Biopharma Inc. filings document a clinical-stage biotechnology issuer focused on telitacicept and autoimmune disease development. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentations, clinical and regulatory updates, material agreements, governance changes and capital-structure matters.
Proxy materials describe director elections, equity incentive plan matters, auditor ratification and annual-meeting voting procedures. Other filings address executive compensation arrangements, Nasdaq-listed common stock, a reverse stock split, equity plan share adjustments and security-holder rights tied to the company’s common stock and outstanding awards.
Vor Biopharma Inc. director Sarah Burgess Reed was granted a stock option on 09/08/2025 to purchase 60,000 shares of common stock at an exercise price of $1.98 per share. The option vests in 36 equal monthly installments beginning on the grant date and is exercisable through 09/07/2035. The filing notes Ms. Reed holds the option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., and she disclaims beneficial ownership because any net proceeds will be turned over to the adviser to offset advisory fees. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/10/2025.
Amendment No. 2 to Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman collectively beneficially own 35,476,939 shares of Vor Biopharma Inc., representing 28.0% of the outstanding common stock. The amendment reports open-market sales by Reprogrammed Interchange LLC from August 25, 2025 through September 5, 2025 that reduced the reporting persons' stake by more than one percentage point. Recent dispositions total 3,497,162 shares sold in multiple transactions at weighted average prices around $2.00 per share. The filing amends prior Schedule 13D disclosures and otherwise leaves earlier statements unchanged.
Amendment No. 2 to Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman collectively beneficially own 35,476,939 shares of Vor Biopharma Inc., representing 28.0% of the outstanding common stock. The amendment reports open-market sales by Reprogrammed Interchange LLC from August 25, 2025 through September 5, 2025 that reduced the reporting persons' stake by more than one percentage point. Recent dispositions total 3,497,162 shares sold in multiple transactions at weighted average prices around $2.00 per share. The filing amends prior Schedule 13D disclosures and otherwise leaves earlier statements unchanged.
Amendment No. 2 to Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman collectively beneficially own 35,476,939 shares of Vor Biopharma Inc., representing 28.0% of the outstanding common stock. The amendment reports open-market sales by Reprogrammed Interchange LLC from August 25, 2025 through September 5, 2025 that reduced the reporting persons' stake by more than one percentage point. Recent dispositions total 3,497,162 shares sold in multiple transactions at weighted average prices around $2.00 per share. The filing amends prior Schedule 13D disclosures and otherwise leaves earlier statements unchanged.
Amendment No. 2 to Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman collectively beneficially own 35,476,939 shares of Vor Biopharma Inc., representing 28.0% of the outstanding common stock. The amendment reports open-market sales by Reprogrammed Interchange LLC from August 25, 2025 through September 5, 2025 that reduced the reporting persons' stake by more than one percentage point. Recent dispositions total 3,497,162 shares sold in multiple transactions at weighted average prices around $2.00 per share. The filing amends prior Schedule 13D disclosures and otherwise leaves earlier statements unchanged.
Vor Biopharma Inc. (VOR) filing an initial Form 3 by reporting person Sarah Burgess Reed shows she is identified as a director and that, as of the event date 08/27/2025, no securities are beneficially owned by her. The filing is marked as an initial statement and was signed on 09/08/2025 by an attorney-in-fact, Sherell Bacchas.
This is a routine Section 16 disclosure showing the reporting relationship and a declaration of zero ownership of the issuer's equity. The form does not report any derivative holdings, purchases, sales, or other transactions and contains no financial tables or material transaction details.
Vor Biopharma Inc. (VOR) Form 4: Reprogrammed Interchange LLC and Reid Hoffman reported a series of open-market sales of common stock in early September 2025. Reprogrammed sold 554,612 shares on 09/03/2025 at a weighted average price of $1.9961, 453,016 shares on 09/04/2025 at $1.9285, and 400,000 shares on 09/05/2025 at $1.9682. Following these transactions, Reprogrammed's reported beneficial ownership decreased from 36,329,955 shares to 35,476,939 shares. The filing notes that Reid Hoffman may be deemed a beneficial owner of shares held by Reprogrammed but disclaims ownership except for pecuniary interest.
Vor Biopharma Inc. Form 144 notifies the market that a person identified as Audrey Skillern intends to sell 23,000,000 common shares on or about 09/03/2025 on NASDAQ. The filing lists an aggregate market value of $46,115,000 for the shares and reports 126,683,111 shares outstanding for the issuer.
The shares were acquired from the company in a private placement on 12/26/2024 and fully paid in cash on that date. The filer reports no securities sold in the past three months. The notice includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.
Vor Biopharma Inc. furnished a new corporate presentation to the investment community, dated September 2025, and made it available on its website. The materials are provided under Item 7.01 of a current report and are attached as Exhibit 99.1. The company notes that this information, including Exhibit 99.1, is being furnished rather than filed under the securities laws and will only be incorporated into other filings if specifically referenced.
Amendment No. 1 to a Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman together beneficially own 36,884,567 shares of Vor BioPharma Inc., representing 29.1% of the outstanding Common Stock. The amendment reports open-market sales by Reprogrammed Interchange LLC from August 25–28, 2025, totaling 2,089,534 shares. Reported weighted-average sale prices were $2.1163 on August 25, $2.0808 on August 26, $2.0053 on August 27 and $2.0115 on August 28. The filing states these sales reduced the Reporting Persons' holdings by more than one percent of the outstanding shares and otherwise incorporates prior Schedule 13D disclosures.
Amendment No. 1 to a Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman together beneficially own 36,884,567 shares of Vor BioPharma Inc., representing 29.1% of the outstanding Common Stock. The amendment reports open-market sales by Reprogrammed Interchange LLC from August 25–28, 2025, totaling 2,089,534 shares. Reported weighted-average sale prices were $2.1163 on August 25, $2.0808 on August 26, $2.0053 on August 27 and $2.0115 on August 28. The filing states these sales reduced the Reporting Persons' holdings by more than one percent of the outstanding shares and otherwise incorporates prior Schedule 13D disclosures.
Vor Biopharma insider report: Reprogrammed Interchange LLC sold common stock on 08/27/2025 and 08/28/2025, and the report lists Reid Hoffman as a person who may be deemed a beneficial owner of shares held by Reprogrammed. The entity sold 611,647 shares on 08/27/2025 at a weighted average price of $2.0053 and sold 806,351 shares on 08/28/2025 at a weighted average price of $2.0115. After the 08/27 trades, Reprogrammed beneficially owned 37,690,918 shares; after the 08/28 trades it reported 36,884,567 shares. The filings state the 08/27 sales ranged from $1.99 to $2.10 and the 08/28 sales ranged from $1.95 to $2.075, and that full trade-level information will be provided upon request. The Form 4 is signed by Frank Huang as manager of Reprogrammed Interchange LLC and by Reid Hoffman, each dated 08/29/2025.
Reprogrammed Interchange LLC, an entity associated with Reid Hoffman, reported sales of common stock of Vor Biopharma Inc. (VOR) on August 25-26, 2025. The filing shows 387,346 shares sold on 08/25/2025 at a weighted average price of $2.1163, and 284,190 shares sold on 08/26/2025 at a weighted average price of $2.0808. Following the 08/25 sale the filing reports 38,586,755 shares beneficially owned by Reprogrammed and after the 08/26 sale 38,302,565 shares were reported.
The filer states the shares are held by Reprogrammed Interchange LLC and that Reid Hoffman may be deemed a beneficial owner by virtue of shared control and indirect pecuniary interest, while disclaiming beneficial ownership except to the extent of his pecuniary interest. The transactions were signed on 08/27/2025 by Frank Huang, Manager of Reprogrammed Interchange LLC, and Reid Hoffman.
Vor Biopharma Inc. reported several changes to its Board of Directors. On August 25, 2025, director Joshua Resnick, M.D. resigned effective immediately, followed on August 26, 2025 by the immediate resignations of directors Matthew Patterson and David Lubner. The company states that each resignation was not due to any disagreement with the company, and the Board expressed appreciation for their years of service.
On August 27, 2025, the Board appointed Sarah Reed as an independent Class II director to fill the vacancy created by Dr. Resnick’s resignation, with a term running until the 2026 annual meeting of stockholders. Reed, age 61, is General Counsel of RA Capital Management, L.P. and has substantial legal and governance experience, including roles at Harvard Law School and the Harvard Yenching Institute. She will receive a $40,000 annual cash retainer and stock options to purchase 60,000 shares of common stock upon appointment, plus options for 30,000 shares at each future annual meeting starting in 2026, under the company’s standard non-employee director compensation policy.